This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read ADMA Biologics’s 8K filing here.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Read More
- Five stocks we like better than ADMA Biologics
- How to Plot Fibonacci Price Inflection Levels
- 3 Momentum Trades for October With Ample Upside Ahead
- What is Forex and How Does it Work?
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- 3 REITs to Buy and Hold for the Long Term
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
